IONIQ Unveils LUNA3, Next-Generation Early-Stage Cancer Detection Platform In News Salt Lake City, UT, June 23, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the... Read More
IONIQ is honored as GHP’s “Most Outstanding Early-Stage Cancer Detection Solutions Provider, 2022” In Awards and Recognition, News Salt Lake City, UT, June 3, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is humbled... Read More
IONIQ Presents Lung Cancer Trial Results at ATS 2022 In News Salt Lake City, UT, May 19, 2022 – IONIQ Sciences is proud of our team members who... Read More
IONIQ hosts Salt Lake City Mayor Mendenhall at its Office In News Salt Lake City, UT, May 2, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) was honored... Read More
IONIQ Sciences hires Edison Group as Investor Relations Advisor In News Salt Lake City, UT, March 17, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today... Read More
IONIQ Sciences announces IP acquisition and License buyout In News Salt Lake City, UT, March 8, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the... Read More
IONIQ’s breast cancer feasibility results published by IEEE In News Salt Lake City, UT, November 30, 2021 – In collaboration with two of our Scientific Advisors, IONIQ... Read More
IONIQ Sciences announces Aaron B. Dorny has joined its Board of Directors In News IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Salt Lake... Read More
IONIQ Sciences Announces Dr. Benjamin Haibe-Kains has joined its Scientific Advisory Committee In News Salt Lake City, UT, September 23, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”),... Read More
IONIQ Sciences Awarded Patent by Canadian Intellectual Property Office In News IONIQ Sciences has received a new Canadian Patent to add to our robust, growing intellectual... Read More